Is there a relationship between dopamine and rhegmatogenous retinal detachment?
3;4-dihydroxyphenylacetic acid; DOPAC; dopamine; dopaminergic amacrine cells; dopaminergic neurotoxicity; macular pucker; oxidative stress; photoreceptor degeneration; rhegmatogenous retinal detachment; vitreous hemorrhage
Journal
Neural regeneration research
ISSN: 1673-5374
Titre abrégé: Neural Regen Res
Pays: India
ID NLM: 101316351
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
26
9
2019
Statut:
ppublish
Résumé
Dopamine and its receptors have been widely studied in the neurological conditions and in the retina. In this study, we evaluated the possible role of dopamine in rhegmatogenous retinal detachment (RRD) by comparing the amount of 3,4-dihydroxyphenylacetic acid (DOPAC), a surrogate index of retinal dopamine levels, in the vitreous sample of patients affected by RRD with those affected by macular pucker and vitreous hemorrhage. Our results showed that significantly higher levels of DOPAC were found in the vitreous sample of patients affected by RRD compared with those affected by vitreous hemorrhage and macular pucker (P = 0.002). Specifically, no trace of the substance was found in vitreous hemorrhage and macular pucker samples. A slightly significant positive correlation was found among DOPAC and post-operative best corrected visual acuity (r = 0.470, P = 0.049). No correlation was found between DOPAC and the days elapsed between diagnosis and surgery (P = 0.317). For the first time our findings suggest that DOPAC is released in RRD, but not in other retinal diseases such as vitreous hemorrhage and macular pucker. Moreover, we showed a correlation between visual acuity outcome and the amount of DOPAC in the vitreous. This might have a potential, although still unknown, implication in the pathogenesis of the disease and/or in the associated photoreceptors loss. This study was approved by the Ethics Committee of Rome Tor Vergata University Hospital (R.S.92.10) on September 24, 2010.
Identifiants
pubmed: 31552904
pii: NeuralRegenRes_2020_15_2_311_265559
doi: 10.4103/1673-5374.265559
pmc: PMC6905326
doi:
Types de publication
Journal Article
Langues
eng
Pagination
311-314Déclaration de conflit d'intérêts
None
Références
Dtsch Arztebl Int. 2014 Jan 6;111(1-2):12-21; quiz 22
pubmed: 24565273
Invest Ophthalmol Vis Sci. 1990 Jan;31(1):67-80
pubmed: 2298543
Exp Eye Res. 1989 Sep;49(3):335-46
pubmed: 2507339
Prog Retin Eye Res. 2017 Nov;61:60-71
pubmed: 28602573
Curr Med Chem. 2019;26(20):3754-3763
pubmed: 29521197
Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):725-32
pubmed: 22829194
Mol Neurobiol. 2016 Aug;53(6):4094-4125
pubmed: 26198567
J Neurochem. 2001 Mar;76(6):1636-44
pubmed: 11259481
Neural Regen Res. 2019 Feb;14(2):197-200
pubmed: 30530997
Exp Eye Res. 2018 Dec;177:208-212
pubmed: 30240584
Doc Ophthalmol. 2004 Jan;108(1):17-40
pubmed: 15104164
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5667-71
pubmed: 8516316
Anal Biochem. 1995 Nov 1;231(2):407-12
pubmed: 8594993
J Comp Neurol. 1992 Apr 8;318(2):147-87
pubmed: 1374766
Exp Eye Res. 2012 Oct;103:33-40
pubmed: 22960317
Mol Vis. 2011;17:1298-304
pubmed: 21633716
Vision Res. 1997 Dec;37(24):3509-29
pubmed: 9425527
Acta Med Okayama. 2008 Jun;62(3):141-50
pubmed: 18596830
Clin Exp Ophthalmol. 2011 Apr;39(3):279-81
pubmed: 20973903
Curr Opin Pharmacol. 2013 Feb;13(1):128-33
pubmed: 22981808
Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2646-55
pubmed: 25010002
Mol Vis. 2013 Aug 07;19:1841-6
pubmed: 23946639
Invest Ophthalmol Vis Sci. 1990 Jan;31(1):54-66
pubmed: 1688834
Int J Mol Sci. 2013 Dec 16;14(12):24438-75
pubmed: 24351827
Eye (Lond). 2018 May;32(5):938-945
pubmed: 29472700
Nutrients. 2019 Feb 28;11(3):
pubmed: 30823449